NESHER, Israel--(BUSINESS WIRE)--NanoVibronix, a medical device company which develops innovative therapeutic ultrasound applications, reported that a study titled "Surface Acoustic Waves Increase the Susceptibility of Pseudomonas Aeruginosa Biofilms to Antibiotic Treatment" has been published in Biofouling by Ehud Banin et al, researchers from the Bar-Ilan University.

The researchers have used Foley catheter segments to grow bacterial biofilm thus simulating the biofilm that grows in indwelling urinary catheters. They then applied SAW (Surface Acoustic Waves) produced by the UroShield device to evaluate its effect on the bacteria along with antibiotics administration.

The UroShield was able to eradicate biofilm bacteria by greater than 85% when applied simultaneously with an antibiotic in three clinically relevant bacterial species. Escherichia coli, Staphylococcus epidermidis and Pseudomonas aeruginosa. Moreover, transcriptome analysis revealed that SAW can alter the transcription pattern of P. aeruginosa, suggesting that this signal can be specifically sensed by the bacterium.

Bacterial urinary tract infections resulting from indwelling urinary catheters have become a major health problem. One of the major issues is bacterial resistance to antibiotic treatments due to biofilm formation on the catheter surfaces, thus enhancing the search for alternative treatments. In the present study, UroShield, a device containing a piezo element capable of transmitting low-frequency surface acoustic waves (SAW) onto the indwelling catheter was used.

"Antibiotic resistance by bacteria is becoming a major risk to patients that require urinary catheter. Our findings show that a medical device can be part of the solution of the vexing problem of antibiotic resistance. UroShield may provide a breakthrough in fighting this major problem," stated Dr. Banin.

"Ultrasonic waves applied to an indwelling urinary catheter are implemented for the first time with NanoVibronix UroShield device and this is expected to reduce the high rate of urinary catheters related infection," says Amir Rippel, Vice President of Marketing at NanoVibronix. "This combined use of a device and antibiotic therapy is a paradigm shift in fighting nosocomial infections and may save patient suffering as well as reduce hospitalization length and its related expenditure."

The UroShield has CE Mark certification and has been submitted for a FDA 510k clearance.

About Nanovibronix

NanoVibronix, located in Nesher Israel, develops and markets medical devices that implement its proprietary therapeutic ultrasound technology. The Company is planning to expand its distribution network and is seeking distributors and marketing partners.